New SCOUT® Mini Reflector Provides Physicians with a Compact Design for Greater Utility
July 07 2022 - 10:00AM
Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global
manufacturer and marketer of healthcare technology, is announcing
the launch of the SCOUT® Mini Reflector. The new mini reflector
measures 8 mm in length—33% shorter than the standard SCOUT
Reflector—offering more utility in difficult-to-localize areas. The
SCOUT Mini Reflector is designed for use in soft tissue, such as
breast and lymph nodes.
In the U.S., more than 300,000 new cases of breast cancer
will be diagnosed in women this year alone.1 Radar
localization procedures help physicians surgically remove abnormal
breast tissue while minimizing trauma to surrounding healthy
tissue. By implanting a tiny reflector, approximately the size of a
grain of rice, physicians can precisely target affected tissue,
which may result in more successful surgeries and improved patient
outcomes.
The SCOUT Mini Reflector offers enhanced directionality to
achieve more precise pinpointing of affected tissue within +/- 1 mm
of accuracy, consistent with Merit’s standard SCOUT reflectors. The
SCOUT Mini Reflector supports multiple treatment needs, including
placement in breast tissue and lymph nodes, and can be used pre- or
post-neoadjuvant chemotherapy, at time of biopsy, and for
bracketing. The SCOUT indication for use also supports placement in
other soft tissue malignancies, broadening the use of SCOUT
technology outside the traditional use for breast cancer
treatment.
“The SCOUT system is already very precise, but the new SCOUT
Mini Reflector is even more directional, allowing me to confidently
take smaller tissue samples while preserving more healthy breast
tissue for the patient,” said Colleen Murphy, MD, FACS, surgical
oncologist at University of Colorado Health and paid consultant of
Merit Medical.
Learn more about the SCOUT Mini Reflector.
The SCOUT Mini Reflector is the newest addition to the Merit
Oncology Breast and Soft Tissue Localization portfolio, which also
includes the standard SCOUT Reflector as part of the SCOUT Radar
Localization system. Since the first clinical use in 2015, SCOUT
has been used successfully in more than 275,000 procedures to date.
Merit Oncology offers a wide range of localization and
brachytherapy technologies to meet diverse clinical needs.
“Merit’s mission is to understand physician needs and innovate
and deliver products that drive better patient outcomes,” said Fred
P. Lampropoulos, Merit Medical’s Chairman and CEO. “Merit
recognized the need for smaller implantable devices for some
physicians and patients. We are pleased to deliver an improved
technology that enhances treatment.”
ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems,
Inc. is engaged in the development, manufacture, and distribution
of proprietary disposable medical devices used in interventional,
diagnostic, and therapeutic procedures, particularly in cardiology,
radiology, oncology, critical care, and endoscopy. Merit serves
client hospitals worldwide with a domestic and international sales
force and clinical support team totaling more than 600 individuals.
Merit employs approximately 6,500 people worldwide.
TRADEMARKS Unless noted otherwise, trademarks and
registered trademarks used in this release are the property of
Merit Medical Systems, Inc. and its subsidiaries in the United
States and other jurisdictions.
CONTACTS
PR/Media Inquiries Sarah Comstock
Merit Medical +1-801-432-2864 |
sarah.comstock@merit.com
Investor Inquiries Mike Piccinino, CFA, IRC Westwicke
- ICR +1-443-213-0509 | mike.piccinino@westwicke.com
1. American Cancer Society. 2022. “Key Statistics for Breast
Cancer.”
https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html
Merit Medical Systems (NASDAQ:MMSI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Merit Medical Systems (NASDAQ:MMSI)
Historical Stock Chart
From Jul 2023 to Jul 2024